Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMANUEL JEAN-MARIE MIGNOT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1023151800
CMS profile
961917
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$47,971.34

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $27,549.24 14
Avadel CNS Pharmaceuticals, LLC $11,180.09 3
Alkermes, Inc. $4,743.27 5
Eisai Inc. $3,000.00 1
SANOFI US SERVICES INC. $1,324.00 1
JAZZ PHARMACEUTICALS INC. $137.65 1
Axsome Therapeutics, Inc. $37.09 1

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMANUEL JEAN-MARIE MIGNOT

NPI 1023151800 · CMS profile ID 961917

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $47,971.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $1,675.0011/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1222569494 CMS
Takeda Pharmaceuticals U.S.A., Inc. $89.6611/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943301 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,500.0011/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223787615 CMS
Alkermes, Inc. $1,340.0010/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223443584 CMS
Alkermes, Inc. $1,650.0010/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223443582 CMS
Alkermes, Inc. $19.1609/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222569486 CMS
Alkermes, Inc. $59.1109/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222569488 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.8409/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223942679 CMS
Takeda Pharmaceuticals U.S.A., Inc. $73.1208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $78.2008/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944438 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,300.0007/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793635 CMS
SANOFI US SERVICES INC. $1,324.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233456988 CMS
Axsome Therapeutics, Inc. $37.0906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235300749 CMS
JAZZ PHARMACEUTICALS INC. $137.6506/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234305277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $86.9306/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944464 CMS
Eisai Inc. $3,000.0006/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244478304 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.2105/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223941865 CMS
Takeda Pharmaceuticals U.S.A., Inc. $106.6605/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943339 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,000.0005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223792304 CMS
Takeda Pharmaceuticals U.S.A., Inc. $65.6203/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944370 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10,422.0002/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223795110 CMS
Avadel CNS Pharmaceuticals, LLC $39.2801/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538514 CMS
Avadel CNS Pharmaceuticals, LLC $3,815.0001/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538510 CMS
Avadel CNS Pharmaceuticals, LLC $7,325.8101/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208538512 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,895.0001/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793497 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,895.0001/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793499 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,292.12 9
PY2020 $14,160.00 5
PY2021 $23,131.44 17
PY2022 $2,844.54 7
PY2023 $4,565.65 9
PY2024 $40,598.94 22
PY2025 $47,971.34 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $992.00 1
PY2025 Principal investigator $2,401,878.07 533
PY2024 Principal investigator $1,022,037.24 254
PY2023 Principal investigator $275,388.22 59
PY2022 Principal investigator $175,960.37 12
PY2021 Principal investigator $361,355.25 19
PY2020 Recipient $3,276.62 36
PY2020 Principal investigator $214,065.50 29
PY2019 Recipient $921.37 2
PY2019 Principal investigator $67,788.78 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $3,111.54 12/31/2021 Non-covered Recipient Entity
STANFORD UNIVERSITY
Clinical Trial to Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants with Narcolepsy Type 1 No dispute reported 06/30/2026 848740815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,111.40 12/15/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) No dispute reported 06/30/2026 816784859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,725.70 11/23/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816779143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,854.30 11/17/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) No dispute reported 06/30/2026 816777707
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,609.10 10/22/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816770987
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,271.70 10/06/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE No dispute reported 06/30/2026 816765053
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $0.90 09/24/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816761441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28,034.10 09/08/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) No dispute reported 06/30/2026 816757785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,014.40 09/03/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816757289
Principal investigator 1 Merck Sharp & Dohme Corporation $9,220.64 08/27/2021 Non-covered Recipient Entity
STANFORD UNIVERSITY
Clinical Trial to Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants with Narcolepsy Type 1 No dispute reported 06/30/2026 848740813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103,382.10 07/23/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816745899
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $93,512.70 06/03/2021 Non-covered Recipient Entity
STANFORD UNIVERSITY
IMPROVING ON THE DETECTION OF NARCOLEPSY THROUGH NOCTURNAL PSG ANALYSIS AND ESTABLISHING A SENSITIVE BIOMARKER FOR OREXIN PHARMACOLOGICAL RESPONSES No dispute reported 06/30/2026 816729947
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,352.41 05/17/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838148715
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.07 05/03/2021 Non-covered Recipient Entity
STANFORD SLEEP MEDICINE CENTER
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838148831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,845.20 04/16/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE No dispute reported 06/30/2026 816710381
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 04/01/2021 Non-covered Recipient Entity
STANFORD SLEEP MEDICINE CENTER
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838148823
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.33 04/01/2021 Non-covered Recipient Entity
STANFORD SLEEP MEDICINE CENTER
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 838148827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,600.10 03/17/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE No dispute reported 06/30/2026 816699381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,690.68 01/26/2021 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 816685633